When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HALO - Subcutaneous Herceptin/Perjeta on par with IV infusion in late-stage study
Halozyme Therapeutics Inc.
A Phase 3 clinical trial, FeDeriCa, evaluating the subcutaneous (SC) administration of a fixed-dose combination of Roche's (OTCQX:RHHBY) Herceptin (trastuzumab) and Perjeta (pertuzumab) plus chemo in patients with HER2-positive early-stage breast cancer showed it to be non-inferior to standard intravenous (IV) infusion plus chemo with no new safety signals.
More news on: Roche Holding AG, Halozyme Therapeutics, Inc., Healthcare stocks news,